ライフサイエンスコーパス: hospitalization

1 ute care (emergency department evaluation or hospitalization).

2 Only 0.86% of patients had an HZ-related hospitalization.

3 ocardiographic evaluation during their index hospitalization.

4 d acute kidney injury (AKI) during the index hospitalization.

5 na with revascularization, and heart failure hospitalization.

6 -cause mortality within 90 days during index hospitalization.

7 ere associated with older age, male sex, and hospitalization.

8 ened among patients with post-procedure MALE hospitalization.

9 had shock, and 588 (3.1%) died during their hospitalization.

10 steroid use and the risk of COVID-19-related hospitalization.

11 pulmonary complications and 5.4% died during hospitalization.

12 schemic stroke, or unstable angina requiring hospitalization.

13 ous coronary intervention use during the AMI hospitalization.

14 ericin B lipid complex during the transplant hospitalization.

15 tic frequently associated with HO-CDI during hospitalization.

16 r CAD, including 3997 (23%) during the index hospitalization.

17 g-term prognosis following infection-related hospitalization.

18 y, or the need for hemodialysis during index hospitalization.

19 capture failures throughout patients' entire hospitalization.

20 ts to fight off pneumonia, a common cause of hospitalization.

21 an intensive care unit, and 6.2% died during hospitalization.

22 time of clinical presentation or during the hospitalization.

23 first psychotic symptom to first psychiatric hospitalization.

24 oriasis and identify factors associated with hospitalization.

25 of SDVs to health disparities on incident HF hospitalization.

26 nificantly higher in the first year after HF hospitalization.

27 patients who received a blood culture during hospitalization.

28 viral load, ameliorate symptoms, and prevent hospitalization.

29 pregnancy and are associated with antepartum hospitalization.

30 R <4.60 ng/ml required dialysis during their hospitalization.

31 ary outcomes included trend of heart failure hospitalizations.

32 tify genetic variants associated with asthma hospitalizations.

33 intervention, and data on complications and hospitalizations.

34 s was associated with a significantly longer hospitalization (0.91 days; P = 0.04).

35 x (LVMi) regression is associated with fewer hospitalizations 1 year after transcatheter aortic valve

36 Among 18,210 pediatric severe sepsis hospitalizations, 1,024 (5.6%) underwent device placemen

37 points (41 valve replacement, 1 death, and 5 hospitalizations-1 chest pain, 2 dyspnea, 1 heart failur

38 Of 18 048 ARFI-coded hospitalizations, 1064 (6%) included RT-PCR testing for

39 Of these hospitalizations, 14.2% of IDU-IE and 1.9% of non-IDU-IE

40 In 2016, of 67,887 discharges after index hospitalizations, 18099 (26.9%) were readmitted within 3

41 ional UK general practice database linked to hospitalizations (1998-2017), 108 638 incident heart fai

42 A total of 5460 hospitalizations (24 937 weighted hospitalizations) clas

43 than general COVID-19 patients (death: 6.6%, hospitalization: 30.1%) and African Americans with COVID

44 Of these hospitalizations, 346 (31.9%) were underreported by the

45 Of 614 influenza-positive ARFI hospitalizations, 35% were in women with low socioeconom

46 zation: 50.7%) than Caucasians (death: 8.6%, hospitalization: 35.2%).

47 n reduction of 59% (IQR, 46-74) in rotavirus hospitalizations, 36% (IQR, 23-47) in AGE hospitalizatio

48 d significantly worse outcomes (death: 9.6%, hospitalization: 41.0%) than general COVID-19 patients (

49 ents was significantly longer than the index hospitalization (5.3 days (5.1-5.5) vs 4.9 days (CI 4.8-

50 Among all IE-SUD hospitalizations, 50.3% had a Staphylococcus aureus infe

51 19 and SUD had worse outcomes (death: 13.0%, hospitalization: 50.7%) than Caucasians (death: 8.6%, ho

52 g hospitalization or within 30 days of prior hospitalization, 555 (12%) within 31 to 90 days, 435 (9%

53 e in an ambulatory setting before subsequent hospitalization, a median of 4.8 days later.

54 Hospitalizations accounted for 35% of total costs among

55 .46 to 1.84) and higher risks of death or HF hospitalization (adjHR: 1.49; 95% CI: 1.09 to 2.02) as w

56 els to examine associations with incident HF hospitalization, adjusting for potential confounders.

57 tion, stroke, all-cause death, heart failure hospitalization after 2 years.

58 ts to fight off pneumonia, a common cause of hospitalization after injury.

59 acute MI, CVD, major bleeding, or all-cause hospitalization after treatment initiation with intravit

60 Hospitalizations after acute myocardial infarction are c

61 ys) that has the highest risk of respiratory hospitalizations after discharge.

62 ys after diagnosis, 6 reported COVID-related hospitalization; all recovered.

63 ventilation without hemodynamic support, and hospitalization alone.

64 data to estimate the burden of enteric fever hospitalization among children aged <15 years and identi

65 cases were associated with cough, apnoea and hospitalization among infants.

66 es of functional status deterioration during hospitalization among nonsurgical critical illness survi

67 l/valsartan in relation to time from last HF hospitalization among patients with HFpEF (>=45%).

68 aths in the immediate 6 months after initial hospitalization among SA children in the Jinja hospital.

69 cally confirmed community-acquired pneumonia hospitalizations among children and adults in eight Unit

70 st laboratory-confirmed influenza-associated hospitalizations among older adults with COPD.

71 he nasal microbiota at bronchiolitis-related hospitalization and 3 later points to the risk of recurr

72 Subsequent heart failure hospitalization and all-cause death were ascertained.

73 al therapy (GDMT) reduced 2-year rates of HF hospitalization and all-cause mortality compared with GD

74 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients wit

75 espiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.

76 -2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease.

77 We measured serum sRAGE level at acute hospitalization and examined its association with intens

78 atients with COVID-19 correlated with longer hospitalization and higher incidence of critical disease

79 y in pediatric populations, prolonging their hospitalization and increasing the healthcare cost.

80 ic status may play a role in events prior to hospitalization and likely does in disposition outcomes.

81 urements that were regularly repeated during hospitalization and measured with a gamma-counter.

82 a pandemic or seasonal influenza in terms of hospitalization and mortality rates, and clinical severi

83 associated with increasingly higher risk for hospitalization and mortality.

84 ciation between polypharmacy and the risk of hospitalization and mortality.

85 cement therapy and often result in long-term hospitalization and nursing home placement.

86 this impacts patient comfort and duration of hospitalization and other associated comorbidities relat

87 Most individuals required hospitalization and presenting symptoms were similar to

88 ss relationships between post-procedure MALE hospitalization and subsequent events.

89 ic delay and unnecessary use of antibiotics, hospitalization and surgery.

90 into groups according to the requirement of hospitalization and surgical intervention.

91 re likely to have severe diseases leading to hospitalization and surgical interventions.

92 when initiated in the high-risk window after hospitalization and warrant prospective validation.

93 nders were defined as those alive without HF hospitalization and with >=20-point improvement in the K

94 nders were defined as those alive without HF hospitalization and with a 5 to <20-point KCCQ-OS improv

95 F and patients who did vs did not die during hospitalization and within 30 days.

96 an follow-up of 5.0 years, 2,028,062 (67.4%) hospitalizations and 459,076 (15.3%) all-cause deaths we

97 The primary outcome was composite total HF hospitalizations and cardiovascular death, analyzed by u

98 combined end point (events) of heart failure hospitalizations and cardiovascular death.

99 , and an increased risk of acute respiratory hospitalizations and early death.

100 risk factor for increased rates of influenza hospitalizations and ED visits.

101 n between source-specific PM and the rate of hospitalizations and emergency department (ED) visits fo

102 Acute health care use (hospitalizations and emergency department use), disease-

103 Costs were driven primarily by more hospitalizations and higher CMV disease-associated costs

104 essed from the Danish national registries on hospitalizations and prescription medication since 1994.

105 Heart failure (HF) is a leading cause of hospitalizations and readmissions in the United States.

106 duces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life co

107 for general medicine, diagnostic procedures, hospitalizations and surgeries, as well as medications a

108 ber of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure tha

109 tion or intravenous diuretics for HF without hospitalization), and with elevated natriuretic peptides

110 arction, stroke, or emergency cardiovascular hospitalization); and 2) self-rated health on the Europe

111 ty of serious morbidity, healthcare seeking, hospitalization, and absenteeism.

112 r coronary revascularization), heart failure hospitalization, and all-cause mortality (Medicare only)

113 Dyspnea, hospitalization, and disease severity were significantly

114 pressures, lower rates of HFH and all-cause hospitalization, and low rates of adverse events across

115 us hospitalizations, 36% (IQR, 23-47) in AGE hospitalizations, and 36% (IQR, 28-46) AGE mortality.

116 98.1% of cardiovascular deaths, 88.6% of all hospitalizations, and 84.4% of hospitalizations for wors

117 ing for coronavirus disease 2019 (COVID-19), hospitalizations, and deaths have emerged as a signal of

118 accines prevent influenza-related illnesses, hospitalizations, and deaths.

119 higher annual all-cause mortality, all-cause hospitalizations, and hospitalization-related mortality

120 ted hospitalization, total infection-related hospitalizations, and mortality between HEU and HUU usin

121 sits, N = 274 226 culture-negative pneumonia hospitalizations, and N = 113 997 culture-negative pneum

122 ss morbidity and the factors associated with hospitalizations are not well known.

123 st of cardiovascular deaths and worsening HF hospitalizations assessed by cardiologists and did not r

124 October 18, 2019, 33 deaths and nearly 1500 hospitalizations associated with e-cigarette use have be

125 LT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TB

126 Death or HF hospitalization at 2 years was lower with TMVr versus co

127 month and the composite rate of death or HF hospitalization between 1 month and 2 years in the COAPT

128 compared time to cardiovascular death or HF hospitalization between RM patients contacted appropriat

129 , and comorbidities underpredicted all-cause hospitalization by 20% (O:E, 1.20) and cardiovascular ho

130 zation by 20% (O:E, 1.20) and cardiovascular hospitalization by 70% (O:E, 1.70) and overpredicted dea

131 cessitated longer hospital stays and greater hospitalization charges.

132 al of 5460 hospitalizations (24 937 weighted hospitalizations) classified as acute decompensated HF h

133 only were more likely to have an antepartum hospitalization compared with those with neither prescri

134 ying event type (acute myocardial infarction hospitalization; coronary artery bypass surgery; heart v

135 ce accounted for more than two-thirds of all hospitalization costs.

136 countries, 32% (2804/8669) of patients with hospitalization data available were hospitalized (Bangla

137 ients with SCC incurred an additional 95,445 hospitalization days resulting a total charge of $609 mi

138 From the simulated infections, we estimated hospitalizations, deaths, and healthcare needs expected,

139 The daily rate of hospitalizations did not change throughout 2019 (-0.01%

140 t boosting models and register data spanning hospitalizations, drug prescriptions and contacts with p

141 We estimated a high burden of hospitalization due to enteric fever among children aged

142 stand the drivers of wait-list mortality and hospitalization due to heart failure.

143 design and identified patients with a first hospitalization during which they received vancomycin or

144 ause, cardiovascular, and non-cardiovascular hospitalizations during a median follow up of 9.6 years.

145 e the rates and predictors of underreporting hospitalization events during the follow-up period of a

146 During hospitalization, family visits inside or outside the pat

147 mpared rates of first hospitalization, total hospitalizations, first infection-related hospitalizatio

148 flammatory events that rarely result in full hospitalization following an ER visit.

149 The 30-day readmission rate after hospitalization for a sickle cell crisis (SCC) is extrem

150 Black patients have higher rates of hospitalization for acute heart failure than other race/

151 Similarly, the rate of HF hospitalization for Black men and women is nearly 2.5-fo

152 C use was associated with increased risks of hospitalization for bleeding or intracranial hemorrhage.

153 ains high (10%-40%) among children requiring hospitalization for complicated SAM.

154 Hospitalization for CVD was defined as an inpatient or e

155 Early, structured telephone follow-up after hospitalization for heart failure can increase 7-day fol

156 liflozin reduced the combined risk of death, hospitalization for heart failure or an emergent/urgent

157 dence of death from cardiovascular causes or hospitalization for heart failure was lower among those

158 the primary outcome (cardiovascular death or hospitalization for heart failure), total hospitalizatio

159 significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and to

160 cardiovascular and renal outcomes, including hospitalization for heart failure, with this benefit ext

161 of all-cause death, heart attack, stroke, or hospitalization for heart failure.

162 modified after the development of the first hospitalization for HF (HHF).

163 s on left ventricular remodeling, and reduce hospitalization for HF and cardiovascular death in patie

164 phases of UNGD activity were associated with hospitalization for HF in a large sample of patients wit

165 Recent hospitalization for HFpEF identifies patients at high ri

166 gh, with a 5-year survival rate of 25% after hospitalization for HFrEF.

167 r 100 patient years, respectively); rates of hospitalization for infection (29.6% versus 29.3%, respe

168 t of accidental ribavirin overdose requiring hospitalization for monitoring; this patient completed t

169 % CI: 0.59, 0.88), and a 47% lower risk of a hospitalization for other peripheral vascular disease (H

170 ions between ambient air quality and risk of hospitalization for pneumonia in adults in China.

171 The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tra

172 This patient required a 2-week hospitalization for SARS-CoV-2 infection, including 7 da

173 t demographic characteristics and time after hospitalization for SCC.

174 ated with all-cause 30-day readmission after hospitalization for SCC.

175 Rates of hospitalization for serious infections among persons wit

176 entified an optimal window of 44 hours after hospitalization for transfusing COVID-19 patients with h

177 To describe the epidemiology of hospitalizations for acute respiratory infection or febr

178 The adjusted estimate of the burden of hospitalizations for C. difficile infection decreased by

179 Rates of hospitalizations for cardiovascular reasons (RR, 0.91 [9

180 Hospitalizations for endocarditis, central nervous syste

181 or hospitalization for heart failure), total hospitalizations for heart failure, and adverse renal ou

182 h 31, 2020, 6,083 patients experienced 7,187 hospitalizations for primary acute cardiovascular reason

183 , discharge disposition, and charges between hospitalizations for serious infections in patients with

184 Hospitalizations for the subset of DUA-IE identified by

185 88.6% of all hospitalizations, and 84.4% of hospitalizations for worsening HF.

186 ive than TIV in preventing all-cause and P&I hospitalization from NHs during an A/H3N2 predominant se

187 raction and adjudication, we identified 1086 hospitalizations from 639 participants (60.2+/-12 years

188 lood culture collected simultaneously during hospitalizations from February 2017 to March 2018.

189 in the United States with pregnancy-related hospitalizations from January 1, 2007, to September 30,

190 le, a representative sample of United States hospitalizations from January 2010 to September 2015.

191 For nonstroke bleeding-related hospitalizations, greater reductions with edoxaban were

192 ciated with a 14% lower risk for death or HF hospitalization (hazard ratio: 0.86; 95% confidence inte

193 Following hospitalization, he completes cardiac rehabilitation.

194 Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months.

195 ates were used to estimate primary causes of hospitalizations, hospitalization rates, and baseline pa

196 associated with a 32% lower risk of any PAD hospitalization (HR: 0.68; 95% CI: 0.60, 0.77), a 26% lo

197 assessed relative aTIV:TIV effectiveness for hospitalization [i.e., all-cause, respiratory, and pneum

198 The need for hospitalization, ICU care, and mechanical ventilation we

199 insurance in the United States who had a MI hospitalization in 2015 or 2016.

200 tive cohort study of injury deaths following hospitalization in any of the 57 trauma centers in a Can

201 aged <15 years and identify risk factors for hospitalization in Bangladesh.

202 art failure remains the most common cause of hospitalization in older adults, and studies of pharmaco

203 conditions, all with at least one additional hospitalization in the preceding 6 months, to the Coalit

204 ly all on a loop diuretic, and 70% with a HF hospitalization in the previous year.

205 a is the leading cause of antibiotic use and hospitalization in Vietnam.

206 E would have the greatest impact in reducing hospitalizations in adults aged >=65 years, and VC impro

207 inophilia, airway obstruction, and number of hospitalizations in asthmatic patients and sinonasal tis

208 mic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESRD patients treated with or withou

209 There was significant daily decline in hospitalizations in March 2020 (-5.9% per day [95% CI: -

210 ng laboratory-confirmed influenza-associated hospitalizations in people with COPD.

211 difference-in-differences (DID) in influenza hospitalization incidence and absenteeism rates using ge

212 ding 6-week mortality rate ratios (MRRs) and hospitalization incidence rate ratios (IRRs).

213 fidence interval [CI], 1.6-2.8), the rate of hospitalization (incidence rate ratio, 2.8; 95% CI, 1.9-

214 18 patients (31%) died a median 6 days after hospitalization, including 75% of patients who required

215 w organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure

216 ategorized into three groups: routine inward hospitalization, intensive care unit admission, and dece

217 o occurrence of 4 advanced medical outcomes (hospitalization, intensive care unit admission, intubate

218 partment (ED); outcomes of interest included hospitalization, intubation, prolonged stay, sepsis, and

219 cardiovascular death and total heart failure hospitalization), its components, myocardial infarction

220 L reuteri significantly reduced duration of hospitalization (mean reduction of 13.00 days [95% CI, r

221 identified 9,054 patients with HF with 5,839 hospitalizations (mean age 71.1 +/- 12.7 years; 47.7% fe

222 -Hispanic white (81% vs 56%), and had longer hospitalizations (median, 8 vs 6 days).

223 There were at most N = 14 764 influenza hospitalizations, N = 57 522 influenza ED visits, N = 27

224 1 276 adults, 2435 influenza-associated SARI hospitalizations occurred.

225 ffects of liraglutide on the composite of HF hospitalization or cardiovascular death were consistent

226 The rates of hospitalization or death were similar in the two groups.

227 and >=25% decline from baseline, CKD-related hospitalization or death, or ESKD.

228 of 16.16 (95% CI, 6.62-39.46) for PH-related hospitalization or escalation of therapy.

229 ot receive testing for CAD either during the hospitalization or in the 90 days before and after.

230 thin 6 months of a recent decompensation (HF hospitalization or intravenous diuretics for HF without

231 n PARAGON-HF, 622 (13%) were screened during hospitalization or within 30 days of prior hospitalizati

232 .4; 95% CI, 2.5-22.0), oxygen requirement at hospitalization (OR, 2.9; 95% CI, 1.3-6.7), acute renal

233 olled HIV experienced higher rates and worse hospitalization outcomes.

234 re significantly associated with incident HF hospitalization (P for trend, 0.001).

235 Older patient age (p=0.03), longer hospitalization (p=0.015), and ICU stay at transplantati

236 All-cause hospitalizations per 100 000 beneficiary-years declined

237 y hospitals, thirty-day total episode, index hospitalization, physician, postacute care, and readmiss

238 vely) for aTIV vs TIV, while the respiratory hospitalization rate was similar, in a season where vacc

239 We estimated the community incidence, hospitalization rate, and in-hospital case-fatality rati

240 sociated with higher risk for cardiovascular hospitalization [rate ratio (RR) 1.25, 95% CI: 1.16 to 1

241 Study type influenced RSV-associated hospitalization rates (P=.003), with active surveillance

242 ge in Kaiser Permanente Southern California, hospitalization rates for acute CVD were compared in the

243 urvival, quality of life, and cardiovascular hospitalization rates observed in ATTR-ACT; future proje

244 Daily hospitalization rates were estimated using negative bino

245 P&I and all-cause resident hospitalization rates were lower (adjusted HR 0.80, 95%

246 estimate primary causes of hospitalizations, hospitalization rates, and baseline participant factors

247 was used to identify factors associated with hospitalization rates, including demographics, blood pre

248 g care during 1996-2016, we estimated annual hospitalization rates, time to inpatient mortality or li

249 xhibit higher than average influenza-related hospitalization rates.

250 s with 31 unique estimates of RSV-associated hospitalization rates.

251 ined component payments related to the index hospitalization, readmissions, physician services, and p

252 ation, comorbidities, smoking status, recent hospitalizations, recent accident and emergency (A&E) at

253 Substitutive home hospitalization reduced cost, health care use, and readm

254 high-stress states and of future psychiatric hospitalizations related to stress, more so when persona

255 e mortality, all-cause hospitalizations, and hospitalization-related mortality compared with nonduall

256 The difference in hospitalization-related outcomes between dually and nond

257 D incidence, slow CKD progression, and lower hospitalization risk are needed to benefit patients and

258 ous antiretroviral therapy could have higher hospitalization risk.

259 Compared to all-cause pediatric hospitalizations, severe sepsis hospitalizations were ei

260 of organ involvement and infections, days of hospitalization, supportive care requirements, and perfo

261 ng 2011-2015 seasons through CDC's Influenza Hospitalization Surveillance Network.

262 C have a lower risk for COVID-19 and related hospitalization than those receiving other therapies.

263 resented an increased risk for heart failure hospitalization that warrants further study.

264 in reduced the total number of heart failure hospitalizations that required intensive care (HR, 0.67;

265 sessment, medical charts from HF-adjudicated hospitalizations, the American Hospital Association annu

266 are at risk of invasive infections; however, hospitalizations to treat these infections are frequentl

267 We compared rates of first hospitalization, total hospitalizations, first infection

268 al hospitalizations, first infection-related hospitalization, total infection-related hospitalization

269 sing symptomatic disease currently have only hospitalization treatment, with its high mortality, avai

270 Functional impairments were assessed during hospitalization via direct measurement (cognition, mobil

271 etc.) were identified from physician claims, hospitalization, vital statistics, outpatient prescripti

272 ction (from 114.18 to 93.68 cases per 10,000 hospitalizations), VRE infection (from 24.15 to 15.76 pe

273 the regulations, risk-adjusted mean cost per hospitalization was $3,627 (95% CI, -$681 to $7,934) mor

274 s of QT-prolongation.Incidence of LTA during hospitalization was 3.6%.

275 The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% requ

276 the median (interquartile range) duration of hospitalization was 8 (0-86) days.

277 eier estimate of freedom from cardiovascular hospitalization was 84.2% (95% CI, 80.2%-88.2%) at 15 mo

278 The rate of all-cause hospitalization was also lower following sensor implanta

279 variate adjusted models, post-procedure MALE hospitalization was associated with greater risk of subs

280 or Streptococcus species after bronchiolitis hospitalization was associated with recurrent wheezing b

281 ultures obtained during the donor's terminal hospitalization were evaluated.

282 Causes of hospitalization were predominantly related to cardiovasc

283 Associations of most UNGD metrics with hospitalization were stronger among those with more seve

284 ause, non-cardiovascular, and cardiovascular hospitalizations were associated with older age (>=65 ve

285 s of leukocytosis, prior antibiotic use, and hospitalizations were consistently higher across all sub

286 se pediatric hospitalizations, severe sepsis hospitalizations were eight-fold more likely to involve

287 Trends in these hospitalizations were examined, as were demographic char

288 with COVID-19, who recovered without needing hospitalization, were identified.

289 isk of MI, CVD, major bleeding, or all-cause hospitalization when comparing the risk-adjusted effect

290 ll-cause mortality and heart failure-related hospitalizations while on the wait-list.

291 testing with 30-day all-cause mortality and hospitalization with acute kidney injury or hyperkalemia

292 fects were calculated to compare the cost of hospitalization with and without sepsis.

293 Hospitalization with bronchiolitis without active supple

294 5% CI, 2465-8791) deaths occurred during the hospitalization with candidemia.

295 registries for identification of concomitant hospitalization with IE.

296 evels of C-terminal FGF23 with time to first hospitalization with major infection, defined by hospita

297 Hospitalizations with SUDs increased from 1.1 to 2.1 per

298 ociated with worse outcomes for death during hospitalization, within 30-days and within 12-months (al

299 re disease (eg, ARDS or pneumonia) requiring hospitalization without an explanatory diagnosis can be

300 aureus infection, compared with 19.4% of IE hospitalizations without SUDs.